May 12, 2017 10:24 AM EDT
News Briefing

Capri­cor shares blast­ed as PhII heart study fails; Sanofi to de­stroy un­used fa­cil­i­ty in France

Shehla Shakoor

Managing Director

→ Af­ter look­ing over dis­ap­point­ing in­ter­im re­sults from its Phase II study of CAP-1002 for im­prov­ing out­comes for heart at­tack pa­tients, Capri­cor $CAPR is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times